zumilokibart (APG777) / AbbVie - LARVOL DELTA

Zumilokibart Suppresses Key IL-13-Mediated Pathogenic Drivers of Eosinophilic Esophagitis in Esophageal Cell Models (ACG 2026) - "Introduction: IL-13 is a central mediator of eosinophilic esophagitis (EoE) pathophysiology, and its blockade with biologic agents such as dupilumab has demonstrated clinical efficacy in EoE. IL-13 stimulation of epithelial ALI cultures disrupted barrier integrity and led to dysregulated expression of loricrin, calpain-14, and desmoglein-1. IL-13 stimulation of both epithelial and smooth muscle cells induced robust secretion of both eotaxin-3 and periostin. In preclinical models, zumilokibart preserved the epithelial barrier, normalized expression of key barrier genes (loricrin, calpain-14, and desmoglein-1), and potently inhibited eotaxin-3 and periostin secretion from epithelial and smooth muscle cells."

Eosinophilic Esophagitis • Gastrointestinal Disorder • Immunology • Inflammation • CAPN1 • IL13 • LORICRIN • POSTN

Efficacy and Safety of Zumilokibart (APG777), a Half-Life-Extended Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis: Primary Results From the Phase 2 APEX Part B Dose-Regimen-Finding Study (EADV 2026) - No abstract available

Clinical • Late-breaking abstract • P2 data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • IL13

An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - P1 | N=86 | Active, not recruiting | Sponsor: Apogee Therapeutics, Inc. | Trial primary completion date: Dec 2026 ➔ Aug 2026

Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Efficacy of Zumilokibart (APG777) in Patients with Atopic Dermatitis and Evidence of Type 2 Inflammatory Comorbidities: Results from the Phase 2 APEX Part A Study (EADV 2026) - No abstract available

Clinical • P2 data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Responders to Zumilokibart (APG777) Show Durable Maintenance and Deepening of Response Beyond Week 16: Results from the Phase 2 APEX Part A Study in Atopic Dermatitis (EADV 2026) - No abstract available

Clinical • P2 data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Zumilokibart (APG777) Provides Robust, Progressive Improvement in the Signs and Symptoms of Atopic Dermatitis: 52-Week Results from the Phase 2 APEX Part A Study (EADV 2026) - No abstract available

P2 data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Late Breaking Abstract - A single dose of zumilokibart (APG777) durably suppresses FeNO through 32 weeks in patients with mild-to-moderate asthma (ERS 2026) - P1 | "A single dose of zumilokibart rapidly and durably suppressed FeNO through 32 weeks, with sustained suppression through 48 weeks in participants with available follow-up, accompanied by reductions in type 2 biomarkers. These findings support evaluation of extended dosing intervals, including 12-, 24-, and 48-week dosing, in patients with moderate-to-severe asthma."

Clinical • Late-breaking abstract • Asthma • Immunology • Inflammation • Respiratory Diseases • IL13

Zumilokibart (APG777), a half-life extended monoclonal antibody, improves IL-13–driven airway pathology in preclinical asthma models (ERS 2026) - "Preclinical data presented here demonstrate that zumilokibart effectively targets key IL-13 driven asthma mechanisms, reducing mucus, eosinophilic infiltration, and inflammatory mediators. These results are in line with zumilokibart Phase 1b data showing rapid and sustained suppression of FeNO in patients with mild-to-moderate asthma."

Preclinical • Asthma • Immunology • Inflammation • Respiratory Diseases • IL13 • POSTN

Zumilokibart (APG777), a half-life extended monoclonal antibody, provides rapid and sustained inhibition of type 2 biomarkers in moderate-to-severe atopic dermatitis (ESDR 2026) - No abstract available

Biomarker • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

554 Responders to Zumilokibart (APG777) Show Durable Maintenance and Deepening of Response Beyond Week 16: Results from the Phase 2 APEX Part A Study in Atopic Dermatitis (ESDR 2026) - No abstract available

Clinical • P2 data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

AbbVie Completes Acquisition of Apogee Therapeutics (AbbVie Press Release) - "Under the terms of the agreement, Apogee shareholders received $135.11 per share in cash, for a total equity value of approximately $10.9 billion....Apogee's lead asset, zumilokibart, is a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitis. Apogee's pipeline also includes APG273, a potential best-in-category long-acting combination targeting IL-13 and thymic stromal lymphopoietin (TSLP), in development for asthma."

M&A • Asthma • Atopic Dermatitis

Apogee announced trial plans for expansion indications in EoE and asthma (GlobeNewswire) - "The ELEVATE Phase 2a trial, an open-label, proof-of-concept study evaluating zumilokibart in patients with eosinophilic esophagitis (EoE), will initiate in 2H 2026. The study is expected to enroll approximately 30 to 50 patients and will assess dosing every three or six months....The ASPIRE Phase 2b trial, a randomized, placebo-controlled study evaluating multiple dosing regimens of zumilokibart in patients with moderate-to-severe asthma with elevated Type 2 biomarkers and a history of exacerbations, will initiate in 1H 2027."

New P2a trial • New P2b trial • Asthma • Eosinophilic Esophagitis • Immunology

Zumilokibart (APG777), a novel, half-life extended anti-IL13 antibody, demonstrates safety and efficacy in moderate-to-severe atopic dermatitis: 16-week results from the phase 2 APEX study (BAD 2026) - P2 | "Treatment with APG777 led to significant improvement in the signs and symptoms of AD and was well tolerated. The primary results of this phase II trial support further evaluation of dosing every 12 weeks or every 24 weeks."

Clinical • P2 data • Atopic Dermatitis • Conjunctivitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Ocular Infections • Ocular Inflammation • Ophthalmology • IL13

Zumilokibart: "Numerically higher absolute response rates and placebo-adjusted efficacy across key endpoints compared to currently marketed AD biologics"; Atopic dermatitis (AbbVie) - Apogee Acquisition Conference Call

P2 data • Atopic Dermatitis • Immunology

Zumilokibart: Initiation of P2a trial for eosinophilic esophagitis in H2 2026 (AbbVie) - Apogee Acquisition Conference Call

New P2a trial • Eosinophilic Esophagitis • Immunology

AbbVie to Acquire Apogee Therapeutics for $10.9B, Adds late‑stage IL‑13 asset Zumilokibart (TradingView) - "Deal adds zumilokibart (APG777), a half‑life extended anti‑IL‑13 with positive Phase 2 AD data and Q12W–Q24W dosing potential; Apogee pipeline includes APG273 (zumilokibart + APG333) targeting asthma; transaction expands AbbVie’s dermatology and respiratory footprint; Transaction expected to close in Q3 2026 subject to regulatory and Apogee shareholder approval; accretive to adjusted diluted EPS beginning in 2032."

M&A • Asthma • Atopic Dermatitis • Chronic Obstructive Pulmonary Disease • Immunology

Early and Sustained Effect of Zumilokibart (APG777) in Atopic Dermatitis and Asthma: 16-Week Results from the Phase 2 APEX Study in Moderate-to-Severe AD and a Phase 1b Study in Mild-to-Moderate Asthma (EAACI 2026) - P1, P2 | "Conclusion Zumilokibart led to early and sustained improvements in markers of disease activity in separate studies in patients with AD and asthma. These results support continued investigation of zumilokibart as a novel therapy for AD and asthma with the potential to reduce injection burden for patients."

P1 data • P2 data • Atopic Dermatitis • Dermatitis • Immunology • IL13

Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis (GlobeNewswire) - "The primary endpoint is the proportion of patients who achieve an Eczema Area and Severity Index (EASI) percent score reduction of at least 75 (EASI-75) at Week 16. Secondary endpoints include Validated Investigator’s Global Assessment (IGA) 0/1, EASI-90, Itch Numeric Rating Scale (I-NRS ≥4), EASI-100, and Very Low Disease Activity (vLDA; EASI-90 + I-NRS 0/1) at Week 16....Based on results from the APEX clinical program, Apogee plans to initiate Phase 3 trials of zumilokibart for moderate-to-severe atopic dermatitis in the second half of 2026, pending regulatory interactions."

New P3 trial • P2 data • Atopic Dermatitis

Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart (The Manila Times) - "The collaboration agreement provides for up to $1.3 billion in flexible, non-dilutive total capital, including up to $800 million of synthetic royalty and up to $500 million of senior debt available at the mutual consent of Apogee and Blackstone."

Financing • Atopic Dermatitis

Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026 (GlobeNewswire)

P2 data • Atopic Dermatitis

Zumilokibart: “Zumi showed >99% IL-13 inhibition; Additionally, zumi produced improvements in lesional skin transcriptome across Type 1, 2, and 3 inflammatory pathways”; Atopic dermatitis (Apogee-Biotechnology) - Corporate Presentation: “Zumilokibart demonstrated deepening of response across all endpoints tested for both every 3-month and every 6-month regimens”

P2 data • Atopic Dermatitis • Dermatology • Immunology

Zumilokibart (APG777), a half-life-extended monoclonal antibody, provides rapid and sustained inhibition of type 2 biomarkers in moderate-to-severe atopic dermatitis (SID 2026) - P2 | "The most notable changes from baseline at Week 16 were observed in IL-13 (Log2FC -7.23), TARC (Log2 FC -2.00), CCL26 (Log2 FC -1.72), and MCP-4 (Log2 FC -0.840). Zumilokibart's rapid and sustained effects on Type 2 biomarkers are consistent with the clinical benefits observed in patients with AD (reported earlier), with only 4 dosing days during induction."

Biomarker • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • IL13

Zumilokibart (APG777) induces rapid and robust normalization of the lesional and non-lesional atopic dermatitis skin phenotype (SID 2026) - P2 | "Zumilokibart demonstrated rapid and broad modulation of immune and barrier AD signatures, improving lesional AD beyond non-lesional skin levels. These results hold promise for rapid and sustained AD disease reversal."

IO biomarker • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus • GJB5 • IFNG • IL10 • IL13 • IL17A • IL22 • IL4R • PIK3CG • PTGER2 • PTGER4 • STAT1 • TJP3 • TRPV2

Pipeline Progress, Corporate Highlights and Upcoming Milestones (GlobeNewswire) - "APEX Phase 2 Part B 16-week data expected in Q2 2026....Part B of the APEX trial is designed to determine the optimized induction dose of zumilokibart, looking at low, medium (Part A dose), and high dose regimens vs. placebo. Results will determine the induction dosing regimen for the planned Phase 3 trials of zumilokibart, expected to initiate in the second half of 2026."

New P3 trial • P2 data • Atopic Dermatitis

Completed $403 million upsized public equity offering (GlobeNewswire) - "Following the Phase 2 APEX Part A readout in March 2026, Apogee closed on an upsized public equity offering, including the full exercise of the underwriters’ option to purchase additional shares, with aggregate gross proceeds of approximately $403 million (before deducting underwriting discounts, commissions, and other offering expenses), which supports cash runway into 2029 through a planned BLA filing for zumilokibart in AD."

FDA filing • Financing • Atopic Dermatitis